A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Arcus Biosciences, Inc.
Merck Sharp & Dohme LLC
City of Hope Medical Center
Pfizer
Pfizer
City of Hope Medical Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
Chinese PLA General Hospital
Abramson Cancer Center at Penn Medicine
University of Southern California
City of Hope Medical Center
Merck Sharp & Dohme LLC
City of Hope Medical Center
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC
University of California, San Francisco
Pancreatic Cancer Action Network
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Takara Bio Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emory University
Lisata Therapeutics, Inc.
University of Chicago
Mayo Clinic
Servier
Coherus Oncology, Inc.
1200 Pharma, LLC
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
University Hospital, Ghent
Chinese PLA General Hospital
Mayo Clinic
University of Chicago
Seagen Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
University of Colorado, Denver
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center